Predictors of First Discharge and Subsequent
Survival in Patients With Automatic Implantable Cardioverter-Defibrillators For a patient to benefit from an AICD, two conditions must be met. First, there must be an appropriate discharge of the device (e.g., because of a hemodynamically destabilizing rhythm such as sustained ventricular tachycardia or fibrillation); second, the patient must survive a reasonable period of time after AICD discharge. For example, no benefit is obtained if the patient dies at the time of first appropriate AICD discharge. Similarly, a patient who never has an AICD discharge may not benefit from the device. Conversely, a patient who survives for an extended period after an AICD discharge probably has enhanced survival attributable to this device.
This study identifies baseline variables associated with the first appropriate AICD discharge as well as those that are associated with extended survival after first discharge. It is anticipated that these findings will help select patients most likely to benefit from AICD placement. Methods 
Patient Population
Two hundred eighteen patients who had an AICD implanted as a single operation or as a planned Defibrillation thresholds were tested before the AICD generator was attached to electrodes. Alternating current was used to induce ventricular tachycardia and/or fibrillation, and decreasing amounts of energy were applied from an external cardioverterdefibrillator across leads so that the minimum energy required to defibrillate the heart was identified (defibrillation threshold). All compare discrete variables where appropriate. The primary analysis was divided into two sections, each with two parts. First, considering the first AICD discharge as the dependent variable, each separate baseline variable was evaluated for its ability to demonstrate significant association with time to first AICD discharge in a univariate actuarial curve analysis. Variables demonstrating sufficient association (p<0.10) were then included in a multivariate stepwise Cox hazards analysis from which an optimum set of variables was derived.
Second, for those patients with an appropriate AICD discharge, using the time of AICD discharge as time zero, a second analysis examining death as the dependent variable was initiated. Again, univariate and multivariate survival methodology was used, with the univariate result determining which baseline variables were included in multivariate testing.
Our multivariate analysis takes into consideration any differences that may be confounding. Thus, even if differences were present among groups in EF, NYHA functional class, or other variables listed and evaluated, the multivariate analysis takes these into consideration. Any significant factors noted in the multivariate analysis on the time to first AICD discharge or on survival after said discharge is that over and above the differences in other variables noted. Limitations A limitation of our study is that electrocardiographic documentations of cardiac rhythm at the time of AICD discharge was not available for all patients. As noted previously, strict criteria for appropriate AICD discharge used by other investigators and by us6710 make it unlikely that we have less than 25%; NYHA class III or IV), were statistically significant between p<0.001 and p< 0.10. These were then tested with a stepwise multivariate Cox model. Only three variables remained significant multivariate predictors of first appropriate AICD discharge. These are also presented in Table 3 . The combination of severe congestive heart failure (NYHA class III or IV) and low EF (less than 25%) before AICD surgery, no coronary artery bypass surgery, and no fl-blocker treatment after hospital discharge were significant positive predictors of first appropriate AICD discharge when applied in a Cox hazards model. A family of derived survival curves is presented in Figure 1 . The proportion of patients without AICD discharge (ordinate) as a function of time (abscissa) are plotted. Evidence or symptoms of myocardial dysfunction (EF, less than 25%; NYHA class III or IV) were associated with an increased likelihood of AICD discharge. This result is consistent with the notion that AICD discharge is determined, in part, by left ventricular function (the interaction of heart failure class and EF). In addition, the presence of anti-ischemic interventions (coronary artery bypass surgery and/or fl-blocker administration) was associated with later AICD discharge.
The relative risk and probability of being free from an AICD discharge at 3 months, 6 months, and 1, 2, and 3 years for patients with various combinations of these factors are presented in f3-blockers. There was a similar range noted for the probability of not having an AICD discharge in the subgroups at each of these times. For example, the 3-year probability varies from 0.75 to 0.13. Thus, the likelihood of having an appropriate AICD discharge early after implantation appears to be a function of severity of left ventricular dysfunction (anatomically as EF and physiologically as NYHA functional class) and anti-ischemic interventions.
It should be noted that several other baseline variables that might be considered important were not significant predictors of AICD discharge. Presenting arrhythmias (ventricular tachycardia versus ventricular fibrillation, baseline and predischarge electrophysiological findings), predischarge Holter findings, number of coronary arteries narrowed, and discharge antiarrhythmic drug status at hospital discharge did not correlate with presence or time to first AICD discharge.
Predictors of Time From First AICD Discharge to Death
To derive benefit from the AICD, there must not only be an appropriate discharge of the AICD device but also prolonged survival after this AICD discharge. One hundred five of the 197 patients who survived AICD implant procedure had an appropriate AICD discharge. Mean survival after AICD discharge was 23.8-+±18.0 months.
Variables that were significant predictors of survival after AICD discharge are listed in Table 5 . Results of multivariate analysis of variables that remained significant predictors of survival after AICD discharge are shown in Table 5 . No patient with concomitant coronary artery bypass graft surgery died in follow-up after an appropriate AICD discharge. Thus, concomitant coronary bypass surgery was the strongest predictor of survival in these patients. Because there were no deaths in this subgroup, no other factor could be analyzed in the presence of concomitant bypass surgery. When patients with bypass surgery were excluded from analysis, three other factors were significant predictors of survival: advanced congestive heart failure class, first-generation AICD generator, and AICD implant as the only surgical procedure (all pc0.05). These data are presented in Figure 2 .
The relative risks and probabilities of survival after first AICD discharge are presented in Table 6 . The relative risk of dying ranged from 2.21 (NYHA class I, concomitant surgery, and newer AICD generator) to 284.98 (NYHA class IV, no concomitant surgery, and first-generation AID generator). Analysis in this manner results in a wide range of probabilities for survival. For example, the probabilities of survival noted ranged from 0.99 to 0.28 at 1 year and from 0.97 to 0.00 at 5 years. With the newer AICD generator, more than 80% of patients survive longer than 1 year after discharge of the device, even in the presence of NYHA class III congestive heart failure. If these class III patients had concomitant surgery, there was a 78% expected survival at 3 years and a 69% expected survival at 5 years. Thus, even patients with moderate to severe symptoms of congestive heart failure secondary to left ventricular dysfunction benefit from the AICD (i.e., they have a significant increment in survival after the first appropriate AICD discharge). It is our premise that two factors must occur for a patient to benefit from AICD placement: The AICD must discharge and successfully convert an episode of ventricular tachycardia or fibrillation, and the patient must survive for a meaningful period of time after this appropriate AICD discharge. Neither the patient who has never had an episode of ventricular tachycardia or ventricular fibrillation that requires AICD use nor the patient who dies soon after an appropriate AICD discharge can be considered to have appreciably benefited from AICD placement. This study is the first to identify baseline variables that are associated with appropriate discharge of an AICD and with enhanced survival after AICD discharge. This two-phase approach, therefore, provides guidelines to help decide when to implant an AICD.
Role of Left Ventrcular Function
Left ventricular function is an important factor that influences both time to first AICD discharge and subsequent survival. Both time to first AICD discharge and survival after this AICD discharge correlated with EF and congestive heart failure class (see Figure 3) . Severe left ventricular dysfunction (EF, less than 25%; p =0.008) and severe congestive heart failure (NYHA class III or IV, p= 0.08) were associated with a higher probability of early AICD discharge. The simultaneous presence of both low EF and advanced congestive heart failure class together was a better predictor of early AICD discharge than either variable alone. These data are consistent with findings of Swerdlow and coworkers,12 who documented a similar relation between left ventricular dysfunction and subsequent arrhythmic events in patients surviving an initial sustained ventricular tachyarrhythmia.
A similar correlation between these two variables and survival after AICD discharge was also present (see Figure 4 ). Lower EF (p=0.06) and congestive heart failure class III or IV (p=0.01) were associated with shorter survival after AICD discharge. Survival after AICD discharge correlated better with heart failure class than with EF or the interaction of these Figure 5 ). Bypass surgery (p=0.035) but not 8-blocker therapy was also associated with improved survival after an AICD discharge (see Figure 6 ). These data are consistent with those of Wilber and coworkers,11 in which coronary bypass surgery after surviving a cardiac arrest was associated with improved survival.
One comment should be made concerning the role of coronary bypass surgery and use of p-blocker therapy.
This is a retrospective analysis of outcome and use of coronary bypass surgery and fl-blocker therapy were not used in a prospective, randomized fashion. In this Time to first appropriate AICD discharge and survival after AICD discharge were independent of underlying cardiac disease. Patients with cardiomyopathy derived benefit from the device similar to that of patients with coronary artery disease. This differs from other reports in which response to antiarrhythmic drug therapy appears to be more effective in patients with coronary artery disease compared with those with dilated cardiomyopathy. [14] [15] [16] [17] Although data of others'0 suggest that survival among patients with appropriate AICD discharges is less than that among patients without shocks, no such differences were noted in our study (mean survival of patients with versus without shocks, 32.8 ± 19.5 months versus 28.0 +19.9 months, respectively; p=NS). Thirty-seven of the 82 deaths reported in our series occurred after the first appropriate AICD discharge, whereas 45 occurred before an AICD discharge.
This study has direct clinical utility because it is the first study to examine which patient will most likely benefit from implantation of the AICD device. In addition, operative mortality associated with AICD placement has been included and was debited from benefit in this study. The probabilities for AICD discharge and survival after AICD discharge allow relatively simple evaluation of prospective patients for AICD implantation and hence provide data that may help define which patients will benefit most from AICD implantation and which patients might be better served by cardiac transplantation and/or ablative maneuvers.
A limitation of the study is that benefit from AICD was not directly compared in a randomized prospective way with that derived from other therapies. Although such a study would be of interest, it was not feasible or ethical in this population of patients, most of whom were referred as treatment failures from other tertiary institutions.
This study is also of importance to help guide therapy during the expected times of limited or fixed resources and cost containment, as the AICD is apparently effective but expensive therapy. Our data suggest that it may be possible to determine which patient will benefit most from an AICD and, perhaps more important, which patient will derive little or no benefit. Thus, the data from this study, if confirmed by others, may help to define subsets of patients who can be triaged not only to best medical therapy but also to the most cost-effective approach.
